CFO Buys $25K in Warrants as Part of Recent Private Placement
APRE sits 35% above its 52-week low of $0.548 on light trading volume (0.3× avg).
Summary
Aprea Therapeutics' CFO, John P. Hamill, purchased $24,999 worth of pre-funded and common warrants, participating in the company's recently announced $30 million private placement.
Key Events · Ownership and Investor Activity · APRE
-
CFO Investment
John P. Hamill, the company's CFO, acquired $24,999 worth of pre-funded and common warrants on March 31, 2026.
-
Participation in Private Placement
This purchase was part of the $30 million private placement announced on March 30, 2026, which significantly extended the company's cash runway and addressed prior financial viability concerns.
-
Insider Confidence Signal
The CFO's personal investment, representing 0.31% of the company's market capitalization, demonstrates conviction in the company's prospects following a crucial financing round.
Analysis · APRE · Life Sciences
This Form 4 filing details the personal investment of Aprea Therapeutics' CFO, John P. Hamill, in the company's recent oversubscribed $30 million private placement. His purchase of nearly $25,000 in pre-funded and common warrants, representing 0.31% of the company's market capitalization, signals strong insider confidence following a critical financing event that addressed the company's going concern risk. This insider buy reinforces the positive sentiment around the successful capital raise.
At the time of this filing, APRE was trading at $0.74 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8.1M. The 52-week trading range was $0.55 to $2.22. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.